Zacks: Analysts Anticipate Biomerica, Inc. (BMRA) Will Announce Quarterly Sales of $1.58 Million
Equities analysts expect Biomerica, Inc. (NASDAQ:BMRA) to post sales of $1.58 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Biomerica’s earnings, with estimates ranging from $1.51 million to $1.65 million. Biomerica posted sales of $1.38 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 14.5%. The firm is expected to announce its next quarterly earnings report on Monday, April 15th.
On average, analysts expect that Biomerica will report full year sales of $5.78 million for the current year, with estimates ranging from $5.61 million to $5.95 million. For the next financial year, analysts anticipate that the company will report sales of $6.08 million, with estimates ranging from $5.79 million to $6.37 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Biomerica.
Biomerica (NASDAQ:BMRA) last posted its quarterly earnings data on Tuesday, January 15th. The company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. Biomerica had a negative net margin of 36.36% and a negative return on equity of 45.72%. The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $1.51 million.
An institutional investor recently bought a new position in Biomerica stock. Heritage Investors Management Corp acquired a new position in shares of Biomerica, Inc. (NASDAQ:BMRA) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,550 shares of the company’s stock, valued at approximately $39,000. Heritage Investors Management Corp owned about 0.17% of Biomerica at the end of the most recent quarter. 0.94% of the stock is currently owned by institutional investors.
Shares of NASDAQ:BMRA traded down $0.09 during trading on Wednesday, reaching $2.57. The stock had a trading volume of 16,500 shares, compared to its average volume of 24,704. Biomerica has a 52 week low of $1.60 and a 52 week high of $4.33. The firm has a market cap of $24.50 million, a P/E ratio of -15.12 and a beta of 1.35.
Biomerica Company Profile
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Recommended Story: Why is a lock-up period needed for an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.